We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00937027
Recruitment Status : Completed
First Posted : July 10, 2009
Last Update Posted : November 5, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to compare the safety and pharmacokinetic properties (the absorption, distribution and excretion) of two preparations of aminopterin (0.25 mg tablets and 1.0 mg tablets) following oral administration by subjects with moderate to severe psoriasis.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Aminopterin Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase 1 Study Comparing The Safety and Oral Pharmacokinetics Of 0.25 mg and 1.0 mg Aminopterin Tablets In Human Subjects With Psoriasis
Study Start Date : June 2009
Primary Completion Date : April 2010
Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Aminopterin one 1.0 mg tablet Drug: Aminopterin
oral tablets, 1.0 mg dose, once weekly, two weeks
Active Comparator: Aminopterin 1 four 0.25 mg tablets Drug: Aminopterin
oral tablets, 1.0 mg dose, once weekly, two weeks

Outcome Measures

Primary Outcome Measures :
  1. Aminopterin area under the curve [ Time Frame: 0.0, 0.5, 1.0, 1.5, 2.0, 3.0, 5.0, 7.0, 10.0 and 12.0 hours ]
  2. Adverse events [ Time Frame: 14 days ]

Secondary Outcome Measures :
  1. Aminopterin concentration maximum, time to maximal aminopterin concentration, aminopterin volume of distribution and aminopterin half-life. [ Time Frame: 0.0, 0.5, 1.0, 1.5, 2.0, 3.0, 5.0, 7.0, 10.0 and 12.0 hours ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Give written informed consent by signing an IRB-approved Informed Consent.
  • Be under treatment for at least moderate to severe psoriasis (diagnosis confirmed by a dermatologist) with MTX (10-20 mg per week) for a minimum of 3 months. Moderate to severe psoriasis is defined here as plaque-type psoriasis affecting a body surface area > 10%.
  • Be 21 years of age or older, but not 60 years of age or older.
  • If participant is female of child bearing potential, then subject must indicate that she is not pregnant.
  • Must be fully informed of the potential for AMT to adversely affect a fetus, and must agree to use highly effective method of birth control beginning at the time of consent, during the study, and for 3 months after leaving the study.
  • Women of childbearing potential may enter the study only after a confirmed menstrual period, and must have a negative urine pregnancy test at the time of screening and within 24 hours of each study drug dose.
  • Have adequate hematologic function as evidenced by the following :results obtained from a blood sample drawn within 2 days of day 0:

    • WBC > 4,500/ mm3
    • Platelet Count > 150,000/mm3
    • Hemoglobin > 12.0 gm/dL
  • Have adequate liver function as evidenced by the following results obtained from a blood sample drawn within 2 days of day 0:

    • AST (SGOT) ≤ 40 IU/L
    • ALT (SGPT) ≤ 40 IU/L
    • Alkaline Phosphatase ≤ 120 IU/L
    • Total Bilirubin ≤ 1.2 mg/dL
  • Have adequate renal function as evidenced by the following result obtained from a blood sample drawn within 2 days of day 0:

    • GFR estimated by Cockcroft-Gault formula:
    • > 90 ml/min (male)
    • > 90 ml/min (female)
  • Have no detectable urine glucose, urine ketones, or urine protein from a sample obtained within 2 days of day 0.
  • Weight of 35 to 90 kg.

Exclusion Criteria:

  • A known history of hepatitis, liver fibrosis or cirrhosis (grades IIIA, IIIB or IV), diabetes (type I or II), HIV infection, tuberculosis, interstitial lung disease, or an abnormal screening chest x-ray that is consistent with interstitial lung disease.
  • Known peptic ulcer, ulcerative colitis or Crohn's disease.
  • Body mass index (BMI) <19.0 or > 35.0 (see appendix C).
  • Within 2 weeks prior to randomization use of any of the following medications that may result in drug/drug interactions with aminopterin: methotrexate, trimethoprim with or without sulfamethoxazole; sulfonamides; sulfonylureas; pyrimethamine; triamethamine; dipyridamole; colchicine; probenecid; aminoglycosides; theophylline; phenytoin; and folinic acid (i.e., leucovorin) unless prescribed by the investigator to treat study drug related toxicity.
  • Within 2 weeks prior to randomization use of salicylates, non-steroidal anti-inflammatory (NSAID) drugs, including Over-The-Counter nonprescription use of aspirin, ibuprofen or naproxen.
  • Use of medications that may be negatively influenced by regular folic acid supplementation such as the anti-epileptics phenobarbital, diphenylhydantoin, and primidone.
  • Use of any investigational medication within 30 days prior to admission to the study.
  • Inability to abstain from alcohol during the study.
  • A history of substance abuse, drug addiction or alcoholism.
  • Unwillingness to use an adequate form of contraception during the study and for 3 months after the study.
  • A female who is pregnant, intends to become pregnant during the study (or within 6 months after study completion), or nursing.
  • Concurrent participation in another clinical trial involving experimental treatment.
  • Current and uncontrolled infection, cardiovascular, pulmonary, hepatic or GI conditions that will interfere with the conduct of the trial or pose an additional morbid risk.
  • Any renal conditions that will interfere with the conduct of the trial or pose an additional morbid risk.
  • Any concurrent disease or condition that in the opinion of the investigator impairs the subject's ability to complete the trial. Psychological, familial, sociological, geographical or medical conditions which, in the Investigator's opinion, could compromise compliance with the objectives and procedures of this protocol or obscure interpretation of the trial's data.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00937027

United States, Texas
Baylor Research Institute
Dallas, Texas, United States, 75246
Sponsors and Collaborators
Syntrix Biosystems, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Alan Menter, M.D. Baylor Research Institute
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Syntrix Biosystems, Inc.
ClinicalTrials.gov Identifier: NCT00937027     History of Changes
Other Study ID Numbers: Syntrix-AMT-PSO-101
NIH Grant #: R43AI068282
First Posted: July 10, 2009    Key Record Dates
Last Update Posted: November 5, 2012
Last Verified: November 2012

Keywords provided by Syntrix Biosystems, Inc.:
Antiinflammatory drug
Autoimmune disease

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action